Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Exposed group:Prophylactic antifungal therapy
Control group:Diagnostic antifungal therapy
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Eligibility
Sex/Gender
All
Age
14 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. confirmed critically ill covid-19; 2. grouping criteria: meet the clinical risk factor combination criteria for invasive candidiasis in critically ill patients proposed by ostrosky-zeichner et al in 2009: (1) the length of stay in ICU exceeds 4 days; (2) in line with two of the following three conditions: broad-spectrum antibiotics; Central venous catheterization; Mechanical ventilation; (3) meeting one of the following six criteria: total parenteral nutrition (day 1 to day 3); Dialysis (1-3 days); Major surgery or pancreatitis or immunosuppression or glucocorticoids (within 7 days).
Exclusion criteria
Exclusion criteria: 1. If the patient received any antifungal treatment (excluding fluconazole or up to 7 days of selective digestion purification therapy) within 14 days prior to randomization, or if there was evidence of IFI; 2. aged < 14 years; 3. pregnant or lactating women; 4. allergy or hypersensitivity to any research drug or excipient; 5. participate in another clinical study or treat with an experimental drug 28 days prior to registration or use an accompanying drug therapy that the investigator considers likely to interfere with the study target.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 14-days mortality;28-days mortality; | — |
Countries
China
Contacts
Public ContactMinghao Fang
Department of Emergency, Tongji Hospital
Outcome results
None listed